Posted by Michael Wonder on 08 Jul 2026
EMA expedites assessment of Revolution Medicines’ daraxonrasib under phased review process
7 July 2026 - Revolution Medicines today announced that EMA's CHMP has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor.
A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.
